Indefinite Delivery Contract SPE2DR25D9912

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain is establishing a Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency (DHA), United States Coast Guard, and US Naval Fleet. The contract, valued at an estimated $30.3 billion, will be awarded to multiple prime vendors on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. The contract will cover a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support normal day-to-day operations, planned and unplanned contingency, Prime Vendor Readiness (PVR), and War Readiness Materiel (WRM) for both CONUS and OCONUS locations. The contract will be a firm-fixed price, requirements-type contract with a 30-month base period and three 30-month option periods. The award will be made on a Lowest Price Technically Acceptable (LPTA) basis, with the possibility of using a reverse auction strategy to obtain the best distribution fees.

Under this IDV, DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, has been awarded a single-award Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including injections, tablets, creams, auto-injectors, and specialty medications, to support the medical supply needs of military health facilities worldwide.